Search

Jun 1, 2024
Immunocore's CEO and Head of R&D discuss the company's PRAME data at #ASCO24
Bahija Jallal and David Berman go over Immunocore's PRAME data in cutaneous melanoma and explain why they believe that the disease...

Jan 8, 2024
Immunocore's CEO on KIMMTRAK sales and expanding into PRAME, autoimmune and more
Bahija Jallal talks about the experience Immunocore has gained commercializing KIMMTRAK since its 2022 approval.

Jan 9, 2023
TCR therapies as a new modality in cancer treatment
Immunocore's Bahija Jallal talks about TCR based therapies at #JPM23.